首药控股（北京）股份有限公司

Group 1 - Company will participate in the 2025 semi-annual performance briefing for the innovative drug industry on September 16, 2025, from 15:00 to 17:00 [2][3][4] - Investors can submit questions for the briefing from September 9 to September 15, 2025, through the Shanghai Stock Exchange Roadshow Center website or via the company's email [2][4] - The briefing will be conducted in an online text interaction format, allowing investors to engage with the company [2][3] Group 2 - The company will hold its first extraordinary general meeting of 2025 on September 15, 2025, at 10:00 AM, with both on-site and online voting options available [8][9] - The meeting will discuss various resolutions, including the approval of the 2025 semi-annual report and the special resolution regarding the cancellation of the supervisory board [11][12][33] - The company emphasizes the importance of shareholder participation and has set up a reminder service to ensure small and medium investors are informed about the meeting [20] Group 3 - The company reported significant progress in its drug development pipeline, focusing on innovative small molecule anti-cancer drugs [37][38] - Key candidates such as SY-707 and SY-5007 have reached important milestones, with SY-5007 preparing for a new drug application submission [39][40] - The company is also expanding its research and development capabilities by establishing a new drug research and industrialization base with an investment of up to 787 million yuan [44][45] Group 4 - The company has maintained a strong financial position, with total assets of 819.45 million yuan and no interest-bearing liabilities as of mid-2025 [46] - Cash management strategies have yielded a return of 9.44 million yuan during the reporting period, ensuring liquidity and safety of funds [46] - The company has actively engaged in investor communication, hosting multiple events to enhance transparency and information dissemination [49][50]